Tirzepatide Prefilled Pen

Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.

Unlike its predecessor Semaglutide (which only targets GLP-1), Tirzepatide showed 5–7% more weight loss in clinical trials. Compared to Retatrutide, a triple agonist, Tirzepatide accomplished nearly the same weight loss but over a longer period (72 weeks vs. 48).

Mechanism of Action

• GLP-1: Suppresses appetite and increases feelings of fullness after eating.
• GIP: Promotes insulin secretion and supports energy balance through receptors in the hypothalamus.

Benefits

• Average weight loss of 24.7% after 72 weeks
• Reduces appetite and cravings
• Enhances satiety and energy balance
• Supports fat oxidation and metabolism
• Improves insulin sensitivity and blood sugar control

Possible Side Effects (often mild and temporary; affected only ~25% in trials)

• Injection site reaction (redness, swelling, itching)
• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite
• Fatigue
• Dyspepsia (indigestion)
• Abdominal pain
• Burping (may have sulfur smell)
• Hair loss

Rare but serious risks

• Thyroid C-Cell Tumors
• Pancreatitis
• Gastroparesis (stomach paralysis)
• Hypoglycemia (if used with insulin)
• Gallbladder disease
• Kidney issues (linked to dehydration)
• Pulmonary aspiration under anesthesia – ALWAYS disclose Tirzepatide use to surgical teams

Contraindications

• Do not use if pregnant or breastfeeding
• Do not use with a personal or family history of Medullary Thyroid Carcinoma or MEN 2 (Multiple Endocrine Neoplasia)
• Do not use if you have Type-1 diabetes, diabetic retinopathy, or severe GI disease
• Do not use if you are allergic or hypersensitive to Tirzepatide